The patients who reached this target had a shorter diabetes duration, lower HbA1c and needed less insulin, suggesting that it is easier to get optimal glycaemic control with BIAsp 30 when prescribing this insulin earlier. The gene discussed is INS; the disease is diabetes mellitus.